Commodore Capital LP
Follow13F filer, CIK 1831942, NEW YORK, NY
Commodore Capital LP reported $1,290,641,676 across 37 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 65.24% of the portfolio.
Accepted , ingested 13F-HR 0001831942-26-000052
- Period
- 2026-09-30
- Reported value
- $1.29B
- Holdings
- 37
- Top 10 weight
- 65.24%
- New
- 11
- Sold out
- 7
Part of the filer group Commodore Capital LP
Commodore Capital Master LPMichael Kramarz
- Commodore Capital Master LP
- Michael Kramarz
- Robert Egen Atkinson
Stakes and trades reported after 2026-09-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- MTRI MENTARI THERAPEUTICS INC: 13G 2,977,630 shares, 5.6% of the class, 13G filed 2026-11-13, 0001831942-26-000046Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| DMRAnew | +1,939,000 | $41.3M |
| SRZNnew | +885,000 | $28.5M |
| KRSAnew | +877,022 | $28.1M |
| SGMTnew | +2,757,742 | $27.2M |
| ADRXnew | +1,260,577 | $25.1M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| AMLXreduced | -3,650,000 | -$106M |
| TNGXexited | -2,250,000 | -$70.3M |
| EYPTexited | -4,600,000 | -$65.8M |
| COGTreduced | -1,785,000 | -$57.2M |
| DMRAexited | -1,939,000 | -$50.4M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0001831942-26-000052, largest first. % of portfolio is the value over $1,290,641,676, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| RLAYRELAY THERAPEUTICS INC | 12,000,000 | $217M | 16.78% | 0 | Timeline | ||
| ELVNENLIVEN THERAPEUTICS INC | 3,275,000 | $150M | 11.63% | 0 | Timeline | ||
| ALKSALKERMES PLC | 2,875,360 | $117M | 9.03% | -124,640 | Timeline | ||
| ANROALTO NEUROSCIENCE INC | 2,723,196 | $69.5M | 5.39% | 0 | Timeline | ||
| SYRESPYRE THERAPEUTICS INC | 700,000 | $62.3M | 4.83% | -146,786 | Timeline | ||
| AMLXAMYLYX PHARMACEUTICALS INC | 2,000,000 | $58.2M | 4.51% | -3,650,000 | Timeline | ||
| LBRXLB PHARMACEUTICALS INC | 1,282,273 | $49.2M | 3.81% | -217,727 | Timeline | ||
| DMRADAMORA THERAPEUTICS INC | 1,939,000 | $41.3M | 3.2% | new | Timeline | ||
| COGTCOGENT BIOSCIENCES INC | 1,265,000 | $40.5M | 3.14% | -1,785,000 | Timeline | ||
| TYRATYRA BIOSCIENCES INC | 1,725,000 | $37.7M | 2.92% | -150,000 | Timeline | ||
| CLDXCELLDEX THERAPEUTICS INC NEW | 1,000,000 | $32.4M | 2.51% | -350,000 | Timeline | ||
| PHVSPHARVARIS N V | 925,000 | $29.3M | 2.27% | -500,000 | Timeline | ||
| SRZNSURROZEN INC | 885,000 | $28.5M | 2.21% | new | Timeline | ||
| KRSAKORSANA BIOSCIENCES INC | 877,022 | $28.1M | 2.17% | new | Timeline | ||
| SGMTSAGIMET BIOSCIENCES INC | 2,757,742 | $27.2M | 2.11% | new | Timeline | ||
| DFTXDEFINIUM THERAPEUTICS INC | 700,000 | $26.6M | 2.06% | -1,300,000 | Timeline | ||
| ADRXADARX PHARMACEUTICALS INC | 1,260,577 | $25.1M | 1.95% | new | Timeline | ||
| EDITEDITAS MEDICINE INC | 8,889,000 | $22.8M | 1.77% | 0 | Timeline | ||
| ENTXENTERA BIO LTD | 7,352,941 | $21.4M | 1.66% | new | Timeline | ||
| ATTOATTOVIA THERAPEUTICS INC | 1,160,000 | $19.9M | 1.54% | new | Timeline | ||
| AGENAGENUS INC | 1,985,387 | $19.7M | 1.53% | new | Timeline | ||
| KYMRKYMERA THERAPEUTICS INC | 175,000 | $19.6M | 1.52% | -75,000 | Timeline | ||
| IFRXINFLARX NV | 9,268,220 | $16.7M | 1.29% | +1,968,220 | Timeline | ||
| AVTXAVALO THERAPEUTICS INC | 1,018,319 | $15.6M | 1.21% | 0 | Timeline | ||
| ANTXAN2 THERAPEUTICS INC | 2,933,680 | $15.6M | 1.21% | 0 | Timeline | ||
| IPSCCENTURY THERAPEUTICS INC | 8,695,652 | $14.9M | 1.15% | 0 | Timeline | ||
| ZURAZURA BIO LTD | 3,250,000 | $13.5M | 1.05% | 0 | Timeline | ||
| IKTINHIBIKASE THERAPEUTICS INC | 5,397,488 | $11.1M | 0.86% | 0 | Timeline | ||
| ASMBASSEMBLY BIOSCIENCES INC | 461,922 | $10.9M | 0.84% | -953,078 | Timeline | ||
| PEPGPEPGEN INC | 4,475,000 | $10.8M | 0.84% | 0 | Timeline | ||
| SABSSAB BIOTHERAPEUTICS INC | 2,870,000 | $9.1M | 0.7% | 0 | Timeline | ||
| RLMDRELMADA THERAPEUTICS INC | 2,350,000 | $8.86M | 0.69% | +925,000 | Timeline | ||
| RACDRESEARCH ALLIANCE CORP IV | 500,000 | $5.79M | 0.45% | new | Timeline | ||
| HLXCHELIX ACQUISITION CORP III | 500,000 | $5.31M | 0.41% | 0 | Timeline | ||
| JTTTJATT III ACQUISITION CORP | 400,000 | $4.41M | 0.34% | new | Timeline | ||
| TCGXTCGX ACQUISITION CORP | 300,000 | $3.75M | 0.29% | new | Timeline | ||
| LONALEONABIO INC | 464,398 | $1.66M | 0.13% | 0 | Timeline |
Sold out in Q3 2026
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| TNGXTANGO THERAPEUTICS INC | 2,250,000 | $70.3M | shares |
| EYPTEYEPOINT INC | 4,600,000 | $65.8M | shares |
| DMRADAMORA THERAPEUTICS INC | 1,939,000 | $50.4M | shares |
| CATXPERSPECTIVE THERAPEUTICS INC | 6,336,782 | $21.6M | shares |
| NUVLNUVALENT INC | 100,000 | $12.3M | shares |
| RACCRESEARCH ALLIANCE CORP III | 500,000 | $5.35M | shares |
| VTGNVISTAGEN THERAPEUTICS INC | 2,788,620 | $630K | shares |
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001831942-26-000052 | base | 2026-11-16 |
Filings
Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13G/A 0001831942-26-000056 | JTTT | 2026-11-16 | ||
| 13G/A 0001831942-26-000055 | RACD | 2026-11-16 | ||
| 13G/A 0001831942-26-000054 | AMLX | 2026-11-16 | ||
| 13G/A 0001831942-26-000053 | LBRX | 2026-11-16 | ||
| 13F-HR 0001831942-26-000052 | Quarter ended 2026-09-30 | 2026-11-16 | ||
| 13G/A 0001831942-26-000051 | VTGN | 2026-11-16 | ||
| 13G/A 0001831942-26-000050 | EYPT | 2026-11-16 | ||
| 13G/A 0001831942-26-000049 | CATX | 2026-11-16 | ||
| 13G/A 0001831942-26-000048 | ANTX | 2026-11-16 | ||
| 13G/A 0001831942-26-000047 | IFRX | 2026-11-16 | ||
| 13G 0001831942-26-000046 | MTRI | 2026-11-13 | ||
| 13G 0001831942-26-000045 | SGMT | 2026-10-07 | ||
| 13G 0001831942-26-000044 | SRZN | 2026-10-01 | ||
| 13F-HR 0001831942-26-000033 | Quarter ended 2026-06-30 | 2026-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-26-000025 | Quarter ended 2026-03-31 | 2026-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-26-000004 | Quarter ended 2025-12-31 | 2026-02-17 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-25-000023 | Quarter ended 2025-09-30 | 2025-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-25-000008 | Quarter ended 2025-06-30 | 2025-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-25-000005 | Quarter ended 2025-03-31 | 2025-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-25-000002 | Quarter ended 2024-12-31 | 2025-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-24-000009 | Quarter ended 2024-09-30 | 2024-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001880562-24-000002 | Quarter ended 2024-06-30 | 2024-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-24-000006 | Quarter ended 2024-03-31 | 2024-05-15 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001831942-24-000003 | Quarter ended 2023-12-31 | 2024-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-24-000002 | Quarter ended 2023-12-31 | 2024-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-23-000011 | Quarter ended 2023-09-30 | 2023-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-23-000009 | Quarter ended 2023-06-30 | 2023-08-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-23-000007 | Quarter ended 2023-03-31 | 2023-05-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-23-000005 | Quarter ended 2022-12-31 | 2023-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-22-000007 | Quarter ended 2022-09-30 | 2022-11-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-22-000006 | Quarter ended 2022-06-30 | 2022-08-15 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-22-000004 | Quarter ended 2022-03-31 | 2022-05-16 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-22-000002 | Quarter ended 2021-12-31 | 2022-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-21-000008 | Quarter ended 2021-09-30 | 2021-11-15 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001831942-21-000007 | Quarter ended 2021-06-30 | 2021-10-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001831942-21-000006 | Quarter ended 2021-03-31 | 2021-10-14 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-21-000005 | Quarter ended 2021-06-30 | 2021-08-16 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-21-000003 | Quarter ended 2021-03-31 | 2021-05-17 | acceptance time not in the bulk data set | |
| 13F-HR 0001831942-21-000002 | Quarter ended 2020-12-31 | 2021-02-16 | acceptance time not in the bulk data set |